Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme
Authors' conclusion
Joint assessment of patients with diabetes in a synchronized cardiometabolic clinic holds promise for enhancing GDMT use and has led to significant reductions in surrogate cardiovascular and renal laboratory biomarkers.
Study context
- Population
- Consecutive patients with T2D and CVD or CKD, assessed simultaneously by an endocrinologist, cardiologist and nephrologist in the same visit; mean age 67 ± 12 years, 69% menfirst patients evaluated
- Participants
- 232 patients
- Exposure
- Guideline-directed medical therapy (GDMT) use before vs after assessment in the synchronized DECIDE-CV clinic
- Outcome
- Use of GDMT (SGLT2i, GLP-1 RA, renin-angiotensin system blockers, mineralocorticoid receptor antagonists) before and after clinic assessment
Methodological detailssingle-group, before-after
- Single-group
- Before-after
Main finding
As reported in the abstract
Use of GDMT
- SGLT2i use, before to after
- from 44% to 87%
- GLP-1 RA use, before to after
- from 8% to 45%
- Renin-angiotensin system blocker use, before to after
- from 77% to 91%
- Mineralocorticoid receptor antagonist use, before to after
- from 25% to 45%
- Significant increase in GDMT use
- p < .01 for all
Observational data: associations, not effects.
Secondary outcomes
Surrogate laboratory biomarkers, baseline to last visit
- HbA1c, urinary albumin-to-creatinine ratio and NT-proBNP significantly dropped from baseline
- P < 0.05 for all
- Patients with paired laboratory data
Original publication
Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme. Diabetes Obes Metab. Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →